To reduce costs and shorten time to market all key operations have been assembled under one roof. Integration allows us to respond dynamically to opportunities and challenges and to reduce dependence on costly outsourcing—ultimately allowing us to take greater control of our timelines.
A major capital and recurring cost in our business is, however, related to manufacturing. Manufacturing infrastructure requires significant capital expenditures, high recurring costs and complex operations. From the onset, we thus set out to develop innovative solutions to these manufacturing hurdles. We sought to incorporate the latest technologies to create the simplest manufacturing process possible. By doing this, we have dramatically reduced infrastructure needs and operating costs going forward.
At XBiotech we plan to deliver a breakthrough treatment to more physicians and patients than any other biological drug to date. By integrating operations, and rethinking how we make drugs, we can crunch timelines and keep operating and infrastructure costs down. In the process, we hope to create a whole new expectation for the cost of drug development—and a whole new value proposition for shareholders.
The plan and core infrastructure is in place to develop the world’s first True Human™ antibody therapy to treat chronic inflammation.
At XBiotech we are indeed excited about the future.
© 2012 XBiotech USA, Inc. | All Rights Reserved